Hannah C. Ainsworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hannah C. Ainsworth has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Carl D. Langefeld
Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, USA
6 shared publications - Floyd H. Chilton
BIO5 Institute, University of Arizona, Tucson, AZ 85721, USA
3 shared publications - Susan Sergeant
Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
3 shared publications - Timothy D. Howard
Department of Biochemistry, Center for Precision Medicine, Wake Forest University School of Medicine, USA
3 shared publications - Ellen. E. Quillen
Wake Forest University School of Medicine, Department of Internal Medicine, Section of Molecular Medicine
2 shared publications - Hillary Fries Huber
Texas Biomedical Research Institute
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in Nature Communications
Multi-omics profiling of primary human B cells activated via distinct stimuli
B cells are central for immunity and immune-mediated diseases (IMD), but how distinct signaling pathways drive diverse activation responses over time is not comprehensively understood. Here, we obtain peripheral blood B cells from 27 female healthy donors for in vitro stimulation, profiling the response at multiple time points using RNA-seq, single-cell RNA-seq with surface protein markers (CITE-seq), and ATAC-seq. Using diverse stimuli including activation of the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and differentiation into double negative 2 (DN2) IgD – CD27 – CD11c + CD21 – B cells, our analyses uncover activation-dependent B cell states, stimulation-specific transcription factors and regulatory regions, the dynamic response of IMD-associated gene expression, and specific open chromatin regions associated with IMD genetic risk. Furthermore, we also identify a lupus risk variant in an enhancer regulating TNFSF4 expression. The analysis data can be accessed via an interactive browser: https://mgalab.shinyapps.io/bcellactivation . Our findings underscore how profiling the full breadth of B cell activation pathways may be important for understanding B cell biology in health and disease.
- 23 October 2026
- Published by Springer Nature in Nature Communications
Open AccessMulti-omics profiling of primary human B cells activated via distinct stimuli
B cells are central for immunity and immune-mediated diseases (IMD), but how distinct signaling pathways drive diverse activation responses over time is not comprehensively understood. Here, we obtain peripheral blood B cells from 27 female healthy donors for in vitro stimulation, profiling the response at multiple time points using RNA-seq, single-cell RNA-seq with surface protein markers (CITE-seq), and ATAC-seq. Using diverse stimuli including activation of the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and differentiation into double negative 2 (DN2) IgD – CD27 – CD11c + CD21 – B cells, our analyses uncover activation-dependent B cell states, stimulation-specific transcription factors and regulatory regions, the dynamic response of IMD-associated gene expression, and specific open chromatin regions associated with IMD genetic risk. Furthermore, we also identify a lupus risk variant in an enhancer regulating TNFSF4 expression. The analysis data can be accessed via an interactive browser: https://mgalab.shinyapps.io/bcellactivation . Our findings underscore how profiling the full breadth of B cell activation pathways may be important for understanding B cell biology in health and disease.
- Open Access
Identification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction
Juvenile idiopathic arthritis (JIA), the most common class of pediatric rheumatic diseases, can lead to joint damage and extra-articular features including uveitis. Early treatment can improve functional outcomes; but many patients do not respond to first-line treatments. We present a JIA Immunochip-based association analysis of rheumatoid factor-negative polyarticular JIA and oligoarticular JIA. This study spans 3,939 cases and 14,412 controls, including 1,123 cases and 1,356 controls not previously analyzed. We identify 41 (14 novel) JIA risk regions and report a JIA polygenic risk score that also associates with age of onset. Functional mechanisms presented include: a novel interaction between HLA-A*02:01 and ERAP2 , cluster-based approach for functional amino acid discovery within HLA-DRB1, and sequence-dependent DNA topology for variant prioritization. We present a comprehensive list of curated gene-drug/small molecule interactions for clinically focused studies. These findings provide a deepened understanding of the genetics of JIA and potential mechanisms to inform precision medicine.
Open AccessIdentification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction
Juvenile idiopathic arthritis (JIA), the most common class of pediatric rheumatic diseases, can lead to joint damage and extra-articular features including uveitis. Early treatment can improve functional outcomes; but many patients do not respond to first-line treatments. We present a JIA Immunochip-based association analysis of rheumatoid factor-negative polyarticular JIA and oligoarticular JIA. This study spans 3,939 cases and 14,412 controls, including 1,123 cases and 1,356 controls not previously analyzed. We identify 41 (14 novel) JIA risk regions and report a JIA polygenic risk score that also associates with age of onset. Functional mechanisms presented include: a novel interaction between HLA-A*02:01 and ERAP2 , cluster-based approach for functional amino acid discovery within HLA-DRB1, and sequence-dependent DNA topology for variant prioritization. We present a comprehensive list of curated gene-drug/small molecule interactions for clinically focused studies. These findings provide a deepened understanding of the genetics of JIA and potential mechanisms to inform precision medicine.
- Open Access
The Non-Human Primate Sample Size Calculator: a design tool for longitudinal research projects
Nonhuman primates (NHP) are crucial models of human health and disease and offer the opportunity to bridge the gap between basic research and the clinic. Given the ethical considerations, high costs, and logistical constraints associated with NHP studies, careful planning is essential to maximize scientific rigor while minimizing animal use. Statistical power calculations, to determine optimal sample size, require knowing the expected number of animals at each timepoint, a challenge for longitudinal studies that must account for natural deaths or disease during a study. Here, we leveraged data from a recent study detailing NHP life- and healthspans to develop a web-based NHP study design tool, available at midas.wakehealth.edu. For 11 NHP species relevant to biomedical research, users can provide study details to generate estimates of sample counts based on natural healthspan trajectories. We envision this tool being used by colony managers and investigators for both study design and monitoring colony health over the course of a study.
Open AccessThe Non-Human Primate Sample Size Calculator: a design tool for longitudinal research projects
Nonhuman primates (NHP) are crucial models of human health and disease and offer the opportunity to bridge the gap between basic research and the clinic. Given the ethical considerations, high costs, and logistical constraints associated with NHP studies, careful planning is essential to maximize scientific rigor while minimizing animal use. Statistical power calculations, to determine optimal sample size, require knowing the expected number of animals at each timepoint, a challenge for longitudinal studies that must account for natural deaths or disease during a study. Here, we leveraged data from a recent study detailing NHP life- and healthspans to develop a web-based NHP study design tool, available at midas.wakehealth.edu. For 11 NHP species relevant to biomedical research, users can provide study details to generate estimates of sample counts based on natural healthspan trajectories. We envision this tool being used by colony managers and investigators for both study design and monitoring colony health over the course of a study.
- Open Access
- 22 July 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (4) , 88
Healthcare experiences and the cycle of genomic healthcare disparities: A cross-sectional study utilizing the ‘All of Us’ research program
Our understanding and utilization of genetics in healthcare continues to increase, but historically excluded and underrepresented groups (e.g., racial minority groups, those living in rural areas, and individuals from lower socioeconomic backgrounds) are often left behind due to barriers in accessing genetic healthcare and research. Although research priorities have shifted toward greater inclusion, underrepresentation persists, potentially driven by ongoing negative healthcare experiences that compound barriers to accessing genetic research and healthcare services, creating a cycle of genomic healthcare disparities. However, there is limited research about how healthcare experiences may contribute to genomic healthcare disparities. We examined this knowledge gap by using data from the All of Us Research Program to investigate healthcare experiences of participants from underrepresented groups as well as participants with clinically diagnosed genetic conditions. We explored three survey questions which documented self-reported experiences when receiving healthcare (i.e., inclusion in medical decisions, being treated with respect by providers, and receiving easy to understand medical information). Survey question responses were analyzed within a regression framework which included self-identified race, age, gender identity, health insurance status, education and income levels, having a diagnosed genetic condition, and rural location as predictors. Results suggest many populations (e.g., minoritized racial and gender groups, individuals who have had to delay care due to living in a rural area, and those with genetic conditions) face inequities in healthcare experiences. These findings support the proposed conceptual model of a genomic healthcare disparity cycle and the need to address these negative healthcare experiences to break the cycle.
- 22 July 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (4) , 88
Open AccessHealthcare experiences and the cycle of genomic healthcare disparities: A cross-sectional study utilizing the ‘All of Us’ research program
Our understanding and utilization of genetics in healthcare continues to increase, but historically excluded and underrepresented groups (e.g., racial minority groups, those living in rural areas, and individuals from lower socioeconomic backgrounds) are often left behind due to barriers in accessing genetic healthcare and research. Although research priorities have shifted toward greater inclusion, underrepresentation persists, potentially driven by ongoing negative healthcare experiences that compound barriers to accessing genetic research and healthcare services, creating a cycle of genomic healthcare disparities. However, there is limited research about how healthcare experiences may contribute to genomic healthcare disparities. We examined this knowledge gap by using data from the All of Us Research Program to investigate healthcare experiences of participants from underrepresented groups as well as participants with clinically diagnosed genetic conditions. We explored three survey questions which documented self-reported experiences when receiving healthcare (i.e., inclusion in medical decisions, being treated with respect by providers, and receiving easy to understand medical information). Survey question responses were analyzed within a regression framework which included self-identified race, age, gender identity, health insurance status, education and income levels, having a diagnosed genetic condition, and rural location as predictors. Results suggest many populations (e.g., minoritized racial and gender groups, individuals who have had to delay care due to living in a rural area, and those with genetic conditions) face inequities in healthcare experiences. These findings support the proposed conceptual model of a genomic healthcare disparity cycle and the need to address these negative healthcare experiences to break the cycle.
- 1 May 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 330 (5) , C1509-C1522
Unacylated ghrelin counteracts mitochondrial dysfunction and neuromuscular junction disruption in cancer cachexia
Unacylated ghrelin prevents muscle wasting and maintains neuromuscular junction integrity and contractile function in cancer cachexia. It enhances mitochondrial respiratory capacity through elevated mitochondrial DNA copy number while limiting DNA mutation. It reduces mitochondrial reactive oxygen species (mtROS) generation, oxidative stress, and proteasome-mediated proteolysis-driven muscle degradation.
- 1 May 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 330 (5) , C1509-C1522
Unacylated ghrelin counteracts mitochondrial dysfunction and neuromuscular junction disruption in cancer cachexia
Unacylated ghrelin prevents muscle wasting and maintains neuromuscular junction integrity and contractile function in cancer cachexia. It enhances mitochondrial respiratory capacity through elevated mitochondrial DNA copy number while limiting DNA mutation. It reduces mitochondrial reactive oxygen species (mtROS) generation, oxidative stress, and proteasome-mediated proteolysis-driven muscle degradation.
- 10 January 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 21 (2) , 98-110
Breaking research silos to achieve equitable precision medicine in rheumatology
Health disparities in rheumatic disease are well established and urgently need addressing. Obstacles to precision medicine equity span both the clinical and the research domains, with a focus placed on structural barriers limiting equitable health care access and inclusivity in research. Less articulated factors include the use of inaccurate population descriptors and the existence of research silos in rheumatology research, which creates a knowledge gap that precludes addressing the health disparities and fulfilling the goals of precision medicine to understand the ‘full patient’. The biopsychosocial model is a research framework that intertwines layers of biological and environmental effects to understand disease. However, very limited rheumatology research bridges across molecular and epidemiological studies of environmental exposures, such as physical and social determinants of health. In this Review, we discuss clinical obstacles to health care equity, including access to health care and the use of inaccurate language when labelling population groups. We explore the goals and data needed for research under the biopsychosocial model. We describe results from a rheumatic disease literature search that highlights the paucity of studies investigating the molecular influences of systemic exposures. We conclude with a list of considerations and recommendations to help achieve equitable precision medicine.
- 10 January 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 21 (2) , 98-110
Breaking research silos to achieve equitable precision medicine in rheumatology
Health disparities in rheumatic disease are well established and urgently need addressing. Obstacles to precision medicine equity span both the clinical and the research domains, with a focus placed on structural barriers limiting equitable health care access and inclusivity in research. Less articulated factors include the use of inaccurate population descriptors and the existence of research silos in rheumatology research, which creates a knowledge gap that precludes addressing the health disparities and fulfilling the goals of precision medicine to understand the ‘full patient’. The biopsychosocial model is a research framework that intertwines layers of biological and environmental effects to understand disease. However, very limited rheumatology research bridges across molecular and epidemiological studies of environmental exposures, such as physical and social determinants of health. In this Review, we discuss clinical obstacles to health care equity, including access to health care and the use of inaccurate language when labelling population groups. We explore the goals and data needed for research under the biopsychosocial model. We describe results from a rheumatic disease literature search that highlights the paucity of studies investigating the molecular influences of systemic exposures. We conclude with a list of considerations and recommendations to help achieve equitable precision medicine.
- Open Access
Comparative lifespan and healthspan of nonhuman primate species common to biomedical research
There is a critical need to generate age– and sex-specific survival curves to characterize chronological aging consistently across nonhuman primates (NHP) used in biomedical research. Accurate measures of chronological aging are essential for inferences into genetic, demographic, and physiological variables driving differences in NHP lifespan within and between species. Understanding NHP lifespans is relevant to public health because unraveling the demographic, molecular, and clinical bases of health across the life course in translationally relevant NHP species is fundamentally important to the study of human aging. Data from more than 110,000 captive individual NHP were contributed by 15 major research institutions to generate sex-specific Kaplan-Meier survival curves using uniform methods in 12 translational aging models: Callithrix jacchus (common marmoset), Chlorocebus aethiops sabaeus (vervet/African green), Macaca fascicularis (cynomolgus macaque), M. fuscata (Japanese macaque), M. mulatta (rhesus macaque), M. nemestrina (pigtail macaque), M. radiata (bonnet macaque), Pan troglodytes spp. (chimpanzee), Papio hamadryas spp. (baboon), Plecturocebus cupreus (coppery titi monkey), Saguinus oedipus (cotton-top tamarin), and Saimiri spp. (squirrel monkey). After employing strict inclusion criteria, primary analysis results are based on 12,269 NHP that survived to adulthood and died of natural/health-related causes. A secondary analysis was completed for 32,616 NHP that died of any cause. For the primary analyses, we report ages of 25th, 50th, 75th, and 85th percentiles of survival, maximum observed ages, rates of survivorship, and sex-based differences captured by quantile regression models and Kolmogorov-Smirnov tests. Our findings show a pattern of reduced male survival among catarrhines (African and Asian primates), especially macaques, but not platyrrhines (Central and South American primates). For many species, median lifespans were lower than previously reported. An important consideration is that these analyses may offer a better reflection of healthspan than lifespan. Captive NHP used in research are typically euthanized for humane welfare reasons before their natural end of life, often after diagnosis of their first major disease requiring long-term treatment with reduced quality of life (e.g., endometriosis, cancer, osteoarthritis). Supporting the idea that these data are capturing healthspan, for several species typical age at onset of chronic disease is similar to the median lifespan estimates. This data resource represents the most comprehensive characterization of sex-specific lifespan and age-at-death distributions for 12 biomedically relevant species, to date. The results clarify the relationships among NHP ages and will provide a valuable resource for the aging research community, improving human-NHP age equivalencies, informing investigators of the expected survival rates of NHP assigned to studies, providing a metric for comparisons in future studies, and contributing to our understanding of the factors that drive lifespan differences within and among species.
Open AccessComparative lifespan and healthspan of nonhuman primate species common to biomedical research
There is a critical need to generate age– and sex-specific survival curves to characterize chronological aging consistently across nonhuman primates (NHP) used in biomedical research. Accurate measures of chronological aging are essential for inferences into genetic, demographic, and physiological variables driving differences in NHP lifespan within and between species. Understanding NHP lifespans is relevant to public health because unraveling the demographic, molecular, and clinical bases of health across the life course in translationally relevant NHP species is fundamentally important to the study of human aging. Data from more than 110,000 captive individual NHP were contributed by 15 major research institutions to generate sex-specific Kaplan-Meier survival curves using uniform methods in 12 translational aging models: Callithrix jacchus (common marmoset), Chlorocebus aethiops sabaeus (vervet/African green), Macaca fascicularis (cynomolgus macaque), M. fuscata (Japanese macaque), M. mulatta (rhesus macaque), M. nemestrina (pigtail macaque), M. radiata (bonnet macaque), Pan troglodytes spp. (chimpanzee), Papio hamadryas spp. (baboon), Plecturocebus cupreus (coppery titi monkey), Saguinus oedipus (cotton-top tamarin), and Saimiri spp. (squirrel monkey). After employing strict inclusion criteria, primary analysis results are based on 12,269 NHP that survived to adulthood and died of natural/health-related causes. A secondary analysis was completed for 32,616 NHP that died of any cause. For the primary analyses, we report ages of 25th, 50th, 75th, and 85th percentiles of survival, maximum observed ages, rates of survivorship, and sex-based differences captured by quantile regression models and Kolmogorov-Smirnov tests. Our findings show a pattern of reduced male survival among catarrhines (African and Asian primates), especially macaques, but not platyrrhines (Central and South American primates). For many species, median lifespans were lower than previously reported. An important consideration is that these analyses may offer a better reflection of healthspan than lifespan. Captive NHP used in research are typically euthanized for humane welfare reasons before their natural end of life, often after diagnosis of their first major disease requiring long-term treatment with reduced quality of life (e.g., endometriosis, cancer, osteoarthritis). Supporting the idea that these data are capturing healthspan, for several species typical age at onset of chronic disease is similar to the median lifespan estimates. This data resource represents the most comprehensive characterization of sex-specific lifespan and age-at-death distributions for 12 biomedically relevant species, to date. The results clarify the relationships among NHP ages and will provide a valuable resource for the aging research community, improving human-NHP age equivalencies, informing investigators of the expected survival rates of NHP assigned to studies, providing a metric for comparisons in future studies, and contributing to our understanding of the factors that drive lifespan differences within and among species.
- Open Access
Nucleic Acid-Sensing and Interferon-Inducible Pathways Show Differential Methylation in MZ Twins Discordant for Lupus and Overexpression in Independent Lupus Samples: Implications for Pathogenic Mechanism and Drug Targeting
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune inflammatory disease with genomic and non-genomic contributions to risk. We hypothesize that epigenetic factors are a significant contributor to SLE risk and may be informative for identifying pathogenic mechanisms and therapeutic targets. To test this hypothesis while controlling for genetic background, we performed an epigenome-wide analysis of DNA methylation in genomic DNA from whole blood in three pairs of female monozygotic (MZ) twins of European ancestry, discordant for SLE. Results were replicated on the same array in four cell types from a set of four Danish female MZ twin pairs discordant for SLE. Genes implicated by the epigenetic analyses were then evaluated in 10 independent SLE gene expression datasets from the Gene Expression Omnibus (GEO). There were 59 differentially methylated loci between unaffected and affected MZ twins in whole blood, including 11 novel loci. All but two of these loci were hypomethylated in the SLE twins relative to the unaffected twins. The genes harboring these hypomethylated loci exhibited increased expression in multiple independent datasets of SLE patients. This pattern was largely consistent regardless of disease activity, cell type, or renal tissue type. The genes proximal to CpGs exhibiting differential methylation (DM) in the SLE-discordant MZ twins and exhibiting differential expression (DE) in independent SLE GEO cohorts (DM-DE genes) clustered into two pathways: the nucleic acid-sensing pathway and the type I interferon pathway. The DM-DE genes were also informatically queried for potential gene–drug interactions, yielding a list of 41 drugs including a known SLE therapy. The DM-DE genes delineate two important biologic pathways that are not only reflective of the heterogeneity of SLE but may also correlate with distinct IFN responses that depend on the source, type, and location of nucleic acid molecules and the activated receptors in individual patients. Cell- and tissue-specific analyses will be critical to the understanding of genetic factors dysregulating the nucleic acid-sensing and IFN pathways and whether these factors could be appropriate targets for therapeutic intervention.
Open AccessNucleic Acid-Sensing and Interferon-Inducible Pathways Show Differential Methylation in MZ Twins Discordant for Lupus and Overexpression in Independent Lupus Samples: Implications for Pathogenic Mechanism and Drug Targeting
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune inflammatory disease with genomic and non-genomic contributions to risk. We hypothesize that epigenetic factors are a significant contributor to SLE risk and may be informative for identifying pathogenic mechanisms and therapeutic targets. To test this hypothesis while controlling for genetic background, we performed an epigenome-wide analysis of DNA methylation in genomic DNA from whole blood in three pairs of female monozygotic (MZ) twins of European ancestry, discordant for SLE. Results were replicated on the same array in four cell types from a set of four Danish female MZ twin pairs discordant for SLE. Genes implicated by the epigenetic analyses were then evaluated in 10 independent SLE gene expression datasets from the Gene Expression Omnibus (GEO). There were 59 differentially methylated loci between unaffected and affected MZ twins in whole blood, including 11 novel loci. All but two of these loci were hypomethylated in the SLE twins relative to the unaffected twins. The genes harboring these hypomethylated loci exhibited increased expression in multiple independent datasets of SLE patients. This pattern was largely consistent regardless of disease activity, cell type, or renal tissue type. The genes proximal to CpGs exhibiting differential methylation (DM) in the SLE-discordant MZ twins and exhibiting differential expression (DE) in independent SLE GEO cohorts (DM-DE genes) clustered into two pathways: the nucleic acid-sensing pathway and the type I interferon pathway. The DM-DE genes were also informatically queried for potential gene–drug interactions, yielding a list of 41 drugs including a known SLE therapy. The DM-DE genes delineate two important biologic pathways that are not only reflective of the heterogeneity of SLE but may also correlate with distinct IFN responses that depend on the source, type, and location of nucleic acid molecules and the activated receptors in individual patients. Cell- and tissue-specific analyses will be critical to the understanding of genetic factors dysregulating the nucleic acid-sensing and IFN pathways and whether these factors could be appropriate targets for therapeutic intervention.
- 1 October 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (10) , S1015-S1016
P16.02 Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience
- 1 October 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (10) , S1015-S1016
P16.02 Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience
- Open Access
- 21 October 2020
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 48 (20) , 11304-11321
Intrinsic DNA topology as a prioritization metric in genomic fine-mapping studies
In genomic fine-mapping studies, some approaches leverage annotation data to prioritize likely functional polymorphisms. However, existing annotation resources can present challenges as many lack information for novel variants and/or may be uninformative for non-coding regions. We propose a novel annotation source, sequence-dependent DNA topology, as a prioritization metric for fine-mapping. DNA topology and function are well-intertwined, and as an intrinsic DNA property, it is readily applicable to any genomic region. Here, we constructed and applied Minor Groove Width (MGW) as a prioritization metric. Using an established MGW-prediction method, we generated a MGW census for 199 038 197 SNPs across the human genome. Summarizing a SNP’s change in MGW (ΔMGW) as a Euclidean distance, ΔMGW exhibited a strongly right-skewed distribution, highlighting the infrequency of SNPs that generate dissimilar shape profiles. We hypothesized that phenotypically-associated SNPs can be prioritized by ΔMGW. We tested this hypothesis in 116 regions analyzed by a Massively Parallel Reporter Assay and observed enrichment of large ΔMGW for functional polymorphisms (P = 0.0007). To illustrate application in fine-mapping studies, we applied our MGW-prioritization approach to three non-coding regions associated with systemic lupus erythematosus. Together, this study presents the first usage of sequence-dependent DNA topology as a prioritization metric in genomic association studies.
- 21 October 2020
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 48 (20) , 11304-11321
Open AccessIntrinsic DNA topology as a prioritization metric in genomic fine-mapping studies
In genomic fine-mapping studies, some approaches leverage annotation data to prioritize likely functional polymorphisms. However, existing annotation resources can present challenges as many lack information for novel variants and/or may be uninformative for non-coding regions. We propose a novel annotation source, sequence-dependent DNA topology, as a prioritization metric for fine-mapping. DNA topology and function are well-intertwined, and as an intrinsic DNA property, it is readily applicable to any genomic region. Here, we constructed and applied Minor Groove Width (MGW) as a prioritization metric. Using an established MGW-prediction method, we generated a MGW census for 199 038 197 SNPs across the human genome. Summarizing a SNP’s change in MGW (ΔMGW) as a Euclidean distance, ΔMGW exhibited a strongly right-skewed distribution, highlighting the infrequency of SNPs that generate dissimilar shape profiles. We hypothesized that phenotypically-associated SNPs can be prioritized by ΔMGW. We tested this hypothesis in 116 regions analyzed by a Massively Parallel Reporter Assay and observed enrichment of large ΔMGW for functional polymorphisms (P = 0.0007). To illustrate application in fine-mapping studies, we applied our MGW-prioritization approach to three non-coding regions associated with systemic lupus erythematosus. Together, this study presents the first usage of sequence-dependent DNA topology as a prioritization metric in genomic association studies.